Evidence map›Paper›PMID 37599351›Full record

ArticleThrombosis journal2023

Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J'xactly study.

Shohei Migita, Yasuo Okumura, Ikuo Fukuda, Mashio Nakamura, Norikazu Yamada, Morimasa Takayama, Hideaki Maeda, Takeshi Yamashita, Takanori Ikeda, Makoto Mo and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thrombosis journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Venous thromboembolisms and stroke risk in patients with atrial fibrillation: a nationwide cohort study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Shohei MigitaDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Ohyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
Yasuo OkumuraDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Ohyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan. okumura.yasuo@nihon-u.ac.jp.
Ikuo FukudaDepartment of Cardiology, Keimeikai Yokawa Hospital, Miki, Japan.
Mashio NakamuraNakamura Medical Clinic, Kuwana, Japan.
Norikazu YamadaDepartment of Cardiology, Kuwana City Medical Center, Kuwana, Japan.
Morimasa TakayamaDepartment of Cardiology, Sakakibara Heart Institute, Fuchu, Japan.
Hideaki MaedaDepartment of Heart and Vascular Center, Ukima Central Hospital, Tokyo, Japan.
Takeshi YamashitaDepartment of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan.
Takanori IkedaDepartment of Cardiovascular Medicine, Toho University Faculty of Medicine, Tokyo, Japan.
Makoto MoDepartment of Cardiovascular Surgery, Yokohama Minami Kyosai Hospital, Yokohama, Japan.
Tsutomu YamazakiInnovation and Research Support Center, International University of Health and Welfare, Tokyo, Japan.
Atsushi HirayamaDepartment of Cardiology, Osaka Police Hospital, Osaka, Japan.
J’xactly Investigators
Nihon University · JPCardiovascular Institute Hospital · JPInternational University of Health and Welfare · JPNakamura Toho Research Institute · JPOsaka Police Hospital · JPSakakibara Hospital · JPSunagawa City Medical Center · JPToho University · JPYokohama Minami Kyosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn established treatment strategy for asymptomatic pulmonary embolism (PE) or deep vein thrombosis (DVT) remains uncertain in Japan; therefore, in this study, we clarify the characteristics and outcomes of symptomatic compared to asymptomatic patients with PE or DVT.

methodsThis prospective, multicenter sub-analysis of the J'xactly study in Japan included 1,016 patients (mean age, 68; 41% male) with venous thromboembolism (VTE) treated with rivaroxaban.

resultsAsymptomatic PE patients (47% of PE patients) were more likely to have active cancer and asymptomatic proximal DVT at lower severity than symptomatic PE patients, despite no differences in age, sex, or the proportion receiving intensive 30 mg/day-rivaroxaban. Patients with asymptomatic DVT (34% of DVT patients) were older, had higher rates of female sex, active cancer, and distal DVT, and received shorter, less intense rivaroxaban treatment. Incidences did not differ between asymptomatic and symptomatic PE patients for recurrent symptomatic VTE (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.22-1.62; P = 0.31) or major bleeding (HR, 0.68; 95% CI, 0.20-2.33; P = 0.58), nor between asymptomatic and symptomatic DVT patients for recurrent symptomatic VTE (HR, 0.56; 95% CI, 0.23-1.40; P = 0.21) and major bleeding (HR, 1.47; 95% CI, 0.54-3.97; P = 0.45).

conclusionsThe real-world composite adverse event rate for treatment with rivaroxaban, as physician-adjusted for dose and duration, was similar for asymptomatic and symptomatic patients regardless of the presence of PE or DVT, suggesting a favorable safety profile for potential rivaroxaban treatment for asymptomatic VTE.

Indexed as

AnticoagulantBleedingRecurrenceRivaroxabanVenous thromboembolism

Identifiers

PMID37599351
PMCPMC10440934
OpenAlexW4386012087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.